Recent advances in understanding idiopathic pulmonary fibrosis.

F1000Research

Volumn 5, Issue , 2016, Pages

  Daccord, Cécile ^a,b   Maher, Toby M ^a,c,d  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BIOLOGICAL MARKER; MATRIX PROTEIN; MICRORNA; NINTEDANIB; PIRFENIDONE;

BRONCHOSCOPY; CANCER MORTALITY; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ENVIRONMENTAL FACTOR; FIBROSING ALVEOLITIS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOME-WIDE ASSOCIATION STUDY; HUMAN; LUNG BIOPSY; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PERSONALIZED MEDICINE; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE;

EID: 85010867816     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.8209.1     Document Type: Review

References (107)

1. Hutchinson J, Fogarty A, Hubbard R, et al.: Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015; 46(3): 795-806.
2. Vancheri C, Failla M, Crimi N, et al.: Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010; 35(3): 496-504.
3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al.: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2083-92.
4. Richeldi L, du Bois RM, Raghu G, et al.: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22): 2071-82.
5. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, et al.: Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther. 2013; 93(3): 252-9.
6. Pathak RR, Davé V: Integrating omics technologies to study pulmonary physiology and pathology at the systems level. Cell Physiol Biochem. 2014; 33(5): 1239-60.
7. Woodcock HV, Maher TM: The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep. 2014; 6: 16.
8. Raghu G, Collard HR, Egan JJ, et al.: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6): 788-824.
9. Hutchinson JP, Fogarty AW, McKeever TM, et al.: In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011 Am J Respir Crit Care Med. 2016; 193(10): 1161-7.
10. Ryerson CJ, Urbania TH, Richeldi L, et al.: Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013; 42(3): 750-7.
11. Tomassetti S, Wells AU, Costabel U, et al.: Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016; 193(7): 745-52.
12. Maher TM, Wells AU, Laurent GJ: Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J. 2007; 30(5): 835-9.
13. Wuyts WA, Antoniou KM, Borensztajn K, et al.: Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med. 2014; 2(11): 933-42.
14. King TE Jr, Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet. 2011; 378(9807): 1949-61.
15. Ahluwalia N, Shea BS, Tager AM: New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med. 2014; 190(8): 867-78.
16. Bagnato G, Harari S: Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2015; 24(135): 102-14.
17. Wolters PJ, Collard HR, Jones KD: Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014; 9: 157-79.
18. Selman M, Pardo A: Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am J Respir Crit Care Med. 2014; 189(10): 1161-72.
19. Wuyts WA, Agostini C, Antoniou KM, et al.: The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J. 2013; 41(5): 1207-18.
20. Ley B, Collard HR, King TE Jr: Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 183(4): 431-40.
21. Maher TM: Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine. Curr Opin Pulm Med. 2013; 19(5): 460-5.
22. du Bois RM, Weycker D, Albera C, et al.: Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011; 184(12): 1382-9.
23. Richeldi L, Ryerson CJ, Lee JS, et al.: Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012; 67(5): 407-11.
24. du Bois RM, Albera C, Bradford WZ, et al.: 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014; 43(5): 1421-9.
25. Wells AU, Desai SR, Rubens MB, et al.: Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003; 167(7): 962-9.
26. du Bois RM, Weycker D, Albera C, et al.: Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184(4): 459-66.
27. Ley B, Ryerson CJ, Vittinghoff E, et al.: A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012; 156(10): 684-91.
28. Ley B, Bradford WZ, Weycker D, et al.: Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45(5): 1374-81.
29. Ley B, Elicker BM, Hartman TE, et al.: Idiopathic pulmonary fibrosis: CT and risk of death. Radiology. 2014; 273(2): 570-9.
30. Salisbury ML, Xia M, Zhou Y, et al.: Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. Chest. 2016; 149(2): 491-8.
31. Kolb M, Collard HR: Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev. 2014; 23(132): 220-4.
32. Win T, Lambrou T, Hutton BF, et al.: 18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials. Eur J Nucl Med Mol Imaging. 2012; 39(3): 521-8.
33. Win T, Thomas BA, Lambrou T, et al.: Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients. Eur J Nucl Med Mol Imaging. 2014; 41(2): 337-42.
34. Ley B, Brown KK, Collard HR: Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014; 307(9): L681-91.
35. Spagnolo P, Tzouvelekis A, Maher TM: Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr Opin Pulm Med. 2015; 21(5): 470-8.
36. Huie TJ, Moss M, Frankel SK: What can biomarkers tell us about the pathogenesis of acute exacerbations of idiopathic pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. 2010; 299(1): L1-2.
37. Naik PK, Bozyk PD, Bentley JK, et al.: Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012; 303(12): L1046-56.
38. Han MK, Zhou Y, Murray S, et al.: Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014; 2(7): 548-56.
39. Maher TM: PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev. 2013; 22(128): 148-52.
40. Jenkins RG, Simpson JK, Saini G, et al.: Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med. 2015; 3(6): 462-72.
41. Fingerlin TE, Murphy E, Zhang W, et al.: Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013; 45(6): 613-20.
42. Noth I, Zhang Y, Ma SF, et al.: Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013; 1(4): 309-17.
43. Roy MG, Livraghi-Butrico A, Fletcher AA, et al.: Muc5b is required for airway defence. Nature. 2014; 505(4783): 412-6.
44. Seibold MA, Wise AL, Speer MC, et al.: A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011; 364(16): 1503-12.
45. Peljto AL, Zhang Y, Fingerlin TE, et al.: Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013; 309(21): 2232-9.
46. Stock CJ, Sato H, Fonseca C, et al.: Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax. 2013; 68(5): 436-41.
47. Kropski JA, Blackwell TS, Loyd JE: The genetic basis of idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45(6): 1717-27.
48. Kropski JA, Pritchett JM, Zoz DF, et al.: Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med. 2015; 191(4): 417-26.
49. Stuart BD, Lee JS, Kozlitina J, et al.: Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med. 2014; 2(7): 557-65.
50. Oldham JM, Ma SF, Martinez FJ, et al.: TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2015; 192(12): 1475-82.
51. Selman M, Pardo A, Barrera L, et al.: Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2006; 173(2): 188-98.
52. Kim SY, Diggans J, Pankratz D, et al.: Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respir Med. 2015; 3(6): 473-82.
53. Boon K, Bailey NW, Yang J, et al.: Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One. 2009; 4(4): e5134.
54. Yang IV, Luna LG, Cotter J, et al.: The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS One. 2012; 7(6): e37708.
55. Meltzer EB, Barry WT, Yang IV, et al.: Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood. BMC Genomics. 2014; 15(1): 902.
56. Huang LS, Mathew B, Li H, et al.: The mitochondrial cardiolipin remodeling enzyme lysocardiolipin acyltransferase is a novel target in pulmonary fibrosis. Am J Respir Crit Care Med. 2014; 189(11): 1402-15.
57. Sanders YY, Ambalavanan N, Halloran B, et al.: Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 186(6): 525-35.
58. Huang SK, Scruggs AM, McEachin RC, et al.: Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung. PLoS One. 2014; 9(9): e107055.
59. Coward WR, Watts K, Feghali-Bostwick CA, et al.: Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol. 2009; 29(15): 4325-39.
60. Coward WR, Watts K, Feghali-Bostwick CA, et al.: Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. Mol Cell Biol. 2010; 30(12): 2874-86.
61. Dakhlallah D, Batte K, Wang Y, et al.: Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med. 2013; 187(4): 397-405.
62. Yang IV, Schwartz DA: Epigenetics of idiopathic pulmonary fibrosis. Transl Res. 2015; 165(1): 48-60.
63. Yang IV, Pedersen BS, Rabinovich E, et al.: Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014; 190(11): 1263-72.
64. Milosevic J, Pandit K, Magister M, et al.: Profibrotic role of miR-154 in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012; 47(6): 879-87.
65. Pandit KV, Corcoran D, Yousef H, et al.: Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010; 182(2): 220-9.
66. Oak SR, Murray L, Herath A, et al.: A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PLoS One. 2011; 6(6): e21253.
67. Cui H, Xie N, Thannickal VJ, et al.: The code of non-coding RNAs in lung fibrosis. Cell Mol Life Sci. 2015; 72(18): 3507-19.
68. Yang G, Yang L, Wang W, et al.: Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression. Gene. 2015; 562(1): 138-44.
69. Li P, Li J, Chen T, et al.: Expression analysis of serum microRNAs in idiopathic pulmonary fibrosis. Int J Mol Med. 2014; 33(6): 1554-62.
70. Montgomery RL, Yu G, Latimer PA, et al.: MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol Med. 2014; 6(10): 1347-56.
71. Kinder BW, Brown KK, McCormack FX, et al.: Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009; 135(6): 1557-63.
72. Barlo NP, van Moorsel CH, Ruven HJ, et al.: Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009; 26(2): 155-61.
73. Yokoyama A, Kondo K, Nakajima M, et al.: Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006; 11(2): 164-8.
74. Prasse A, Probst C, Bargagli E, et al.: Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009; 179(8): 717-23.
75. Vuga LJ, Tedrow JR, Pandit KV, et al.: C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014; 189(8): 966-74.
76. DePianto DJ, Chandriani S, Abbas AR, et al.: Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax. 2015; 70(1): 48-56.
77. Naik PK, Bozyk PD, Bentley JK, et al.: Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012; 303(12): L1046-56.
78. Jaffar J, Unger S, Corte TJ, et al.: Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis. Chest. 2014; 146(4): 1055-63.
79. Rosas IO, Richards TJ, Konishi K, et al.: MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 5(4): e93.
80. Richards TJ, Kaminski N, Baribaud F, et al.: Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 185(1): 67-76.
81. Chien JW, Richards TJ, Gibson KF, et al.: Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J. 2014; 43(5): 1430-8.
82. Ohshimo S, Ishikawa N, Horimasu Y, et al.: Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med. 2014; 108(7): 1031-9.
83. Moeller A, Gilpin SE, Ask K, et al.: Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009; 179(7): 588-94.
84. Reilkoff RA, Peng H, Murray LA, et al.: Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1-induced pulmonary fibrosis. Am J Respir Crit Care Med. 2013; 187(2): 180-8.
85. Saini G, Porte J, Weinreb PH, et al.: αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur Respir J. 2015; 46(2): 486-94.
86. Hara A, Sakamoto N, Ishimatsu Y, et al.: S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respir Med. 2012; 106(4): 571-80.
87. Buckley S, Shi W, Xu W, et al.: Increased alveolar soluble annexin V promotes lung inflammation and fibrosis. Eur Respir J. 2015; 46(5): 1417-29.
88. Song JW, Do KH, Jang SJ, et al.: Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013; 143(5): 1422-9.
89. Nobakht M Gh BF, Aliannejad R, Rezaei-Tavirani M, et al.: The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis. Biomarkers. 2015; 20(1): 5-16.
90. Kottmann RM, Kulkarni AA, Smolnycki KA, et al.: Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-β. Am J Respir Crit Care Med. 2012; 186(8): 740-51.
91. Xie N, Tan Z, Banerjee S, et al.: Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis. Am J Respir Crit Care Med. 2015; 192(12): 1462-74.
92. Baumgartner KB, Samet JM, Stidley CA, et al.: Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997; 155(1): 242-8.
93. Steele MP, Speer MC, Loyd JE, et al.: Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med. 2005; 172(9): 1146-52.
94. Antoniou KM, Hansell DM, Rubens MB, et al.: Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med. 2008; 177(2): 190-4.
95. Taskar VS, Coultas DB: Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc. 2006; 3(4): 293-8.
96. Johannson KA, Vittinghoff E, Lee K, et al.: Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J. 2014; 43(4): 1124-31.
97. Savarino E, Carbone R, Marabotto E, et al.: Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J. 2013; 42(5): 1322-31.
98. Lee JS, Ryu JH, Elicker BM, et al.: Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184(12): 1390-4.
99. Lee JS, Collard HR, Anstrom KJ, et al.: Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013; 1(5): 369-76.
100. Raghu G, Rochwerg B, Zhang Y, et al.: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015; 192(2): e3-19.
101. Molyneaux PL, Maher TM: The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev. 2013; 22(129): 376-81.
102. Lawson WE, Crossno PF, Polosukhin VV, et al.: Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol. 2008; 294(6): L1119-26.
103. Kropski JA, Lawson WE, Blackwell TS: Right place, right time: the evolving role of herpesvirus infection as a "second hit" in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012; 302(5): L441-4.
104. Egan JJ, Adamali HI, Lok SS, et al.: Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: an open pilot study. Pulm Med. 2011; 2011: 240805.
105. Jolly L, Stavrou A, Vanderstoken G, et al.: Influenza promotes collagen deposition via αvβ6 integrin-mediated transforming growth factor β activation. J Biol Chem. 2014; 289(51): 35246-63.
106. Molyneaux PL, Cox MJ, Willis-Owen SA, et al.: The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014; 190(8): 906-13.
107. Shulgina L, Cahn AP, Chilvers ER, et al.: Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013; 68(2): 155-62.